Use of composition containing ACEI in preparing medicine for treating hyperhomocysteinemia injury and related diseases thereof

Abstract

The invention relates to a use of a pharmaceutical composition containing an angiotensin converting enzyme inhibitor and a vitamin in vitamin B family in the preparation of drugs for treating body injuries and the related diseases caused by hyperhomocysteinemia (brain stroke, ischemic heart disease, deep vein thrombosis, and the like), in particular to the drugs for treating the brain stroke. The combined use of the angiotensin converting enzyme inhibitor and the vitamin in the vitamin B family can further inhibit the proliferation of VSMC, improve the symptoms of cerebral ischemia and be better than the single use of the drug, thereby showing that the combined use of the angiotensin converting enzyme inhibitor and the vitamin in the vitamin B can be acted on the different routes and the links for delaying / treating the body injuries and the related diseases caused by Hcy and further having the overlapping effect or the synergy. At present, the single use of folic acid does not have ideal effect in the clinical treatment of high Hcy, the compound drug can be a better choice and can provide a more effective treatment proposal for treating the hyperhomocysteinemia. The use belongs to the field of pharmacy.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing angiotensin-converting enzyme inhibitor (ACEI) and B vitamins used in the preparation and treatment of body damage caused by hyperhomocysteinemia and related diseases (stroke, ischemic heart disease) , deep vein thrombosis, etc.), especially in the use of stroke drugs. belongs to the field of pharmacy. Background technique [0002] Cardiovascular disease (CVD) is not only the main cause of death in developed countries, but also has become one of the main causes of death in developing countries such as China. As early as 1969, it was hypothesized that homocysteine ​​(Hcy, a sulfur-containing amino acid) might be a risk factor for cardiovascular disease. Since then, a large number of studies have accumulated objective evidence that plasma homocysteine Cystine levels are independent of traditional risk factors such as hypertension and hyperlipidemia, and are associated with the risk of car...

AI Technical Summary

Problems solved by technology

[0008] At present, a number of clinical studies on supplementing B vitamins such as folic acid, VB12, and VB6 to reduce Hcy and observe cardiovascular and cerebrovascular end points have been completed. However, contrary to expectations, almost all large-scale clinical studies such as VISP, NORVIT, HOPE2, and WACFAS have not observed As far as the efficacy of folic acid on the composite endpoint of cardiovascular and cerebrovascular events, and even all secondary endpoints, only the HOPE2 study observed possible beneficial results of folic acid on the secondary endpoint, but the author believes that it may not be related to the effect of folic acid

Such a result may be due to two factors: the degree of Hcy reduction is insufficient, and some studies believe that a greater degree of Hcy reduction can obtain better stroke outcomes [Wang X, Qin X, Demirtas H, et al.Efficacy of folic Acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876-1882.]; For the body damage caused by high Hcy, the effect of folic acid alone is not sufficient

Images